Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK

Context Ellagic acid (EA) is used in traditional medicine to treated hyperlipidaemia. Objective This study examined if AMPK mediates the anti-steatotic effect of ellagic acid (EA) in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats. Materials and methods Adult male Wistar rats (130 ± 10...

Full description

Saved in:
Bibliographic Details
Main Authors: Jozaa Z. ALTamimi (Author), Ghedeir M. Alshammari (Author), Nora A. AlFaris (Author), Reham I. Alagal (Author), Dalal H. Aljabryn (Author), Norah A. Albekairi (Author), Mahmoud Ahmad Alkhateeb (Author), Mohammed Abdo Yahya (Author)
Format: Book
Published: Taylor & Francis Group, 2022-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_e4c34b51b708424ca2b701e8970618e6
042 |a dc 
100 1 0 |a Jozaa Z. ALTamimi  |e author 
700 1 0 |a Ghedeir M. Alshammari  |e author 
700 1 0 |a Nora A. AlFaris  |e author 
700 1 0 |a Reham I. Alagal  |e author 
700 1 0 |a Dalal H. Aljabryn  |e author 
700 1 0 |a Norah A. Albekairi  |e author 
700 1 0 |a Mahmoud Ahmad Alkhateeb  |e author 
700 1 0 |a Mohammed Abdo Yahya  |e author 
245 0 0 |a Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK 
260 |b Taylor & Francis Group,   |c 2022-01-01T00:00:00Z. 
500 |a 1388-0209 
500 |a 1744-5116 
500 |a 10.1080/13880209.2021.1990969 
520 |a Context Ellagic acid (EA) is used in traditional medicine to treated hyperlipidaemia. Objective This study examined if AMPK mediates the anti-steatotic effect of ellagic acid (EA) in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats. Materials and methods Adult male Wistar rats (130 ± 10 g) were divided into 6 groups (n = 8 rats/group) as control, control + EA, control + EA + CC an AMPK inhibitor), T1DM, T1DM + EA, and T1DM + EA + CC. The treatments with EA (50 mg/kg/orally) and CC (200 ng/rat/i.p.) were given the desired groups for 12 weeks, daily. Results In T1DM-rats, EA reduced fasting glucose levels (44.8%), increased fasting insulin levels (92.8%), prevented hepatic lipid accumulation, and decreased hepatic and serum levels of total triglycerides (54% & 61%), cholesterol (57% & 48%), and free fatty acids (40% & 37%). It also reduced hepatic levels of ROS (62%), MDA (52%), TNF-α (62%), and IL-6 (57.2%) and the nuclear activity of NF-κB p65 (54%) but increased the nuclear activity of Nrf-2 (4-fold) and levels of GSH (107%) and SOD (87%). Besides, EA reduced downregulated SREBP1 (35%), SREBP2 (34%), ACC-1 (36%), FAS (38%), and HMG-CoAR (49%) but stimulated mRNA levels of PPARα (1.7-fold) and CPT1a (1.8-fold), CPT1b (2.9-fold), and p-AMPK (4-fold). All these events were prevented by the co-administration of CC. Discussion and conclusions These findings encourage the use of EA to treat hepatic disorders, and non-alcoholic fatty liver disease (NAFLD). Further in vivo and in vitro studies are needed to validate its potential in clinical medicine. 
546 |a EN 
690 |a t1dm 
690 |a nafld 
690 |a polyphenols 
690 |a oxidative stress 
690 |a inflammation 
690 |a lipid metabolism 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Pharmaceutical Biology, Vol 60, Iss 1, Pp 25-37 (2022) 
787 0 |n http://dx.doi.org/10.1080/13880209.2021.1990969 
787 0 |n https://doaj.org/toc/1388-0209 
787 0 |n https://doaj.org/toc/1744-5116 
856 4 1 |u https://doaj.org/article/e4c34b51b708424ca2b701e8970618e6  |z Connect to this object online.